Lapatinib D4
| Product Name | Lapatinib D4 |
|---|---|
| Alternate Names | Lapatinib Stable Isotopes, Stable Isotopes of Lapatinib |
| CAT No. | CS-O-32802 |
| CAS No. | 1184263-99-7 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 585.08 g/mol |
| Mol. For. | C₂₉H₂₂D₄ClFN₄O₄S |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Lapatinib |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | ClC1=C(OCC2=CC(F)=CC=C2)C=CC(NC3=NC=NC4=C3C=C(C5=CC=C(CNC([2H])([2H])C([2H])([2H])[S](C)(=O)=O)O5)C=C4)=C1 |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Lapatinib D4 is a deuterated derivative of Lapatinib, which is a small molecule kinase inhibitor used in the treatment of breast cancer. Lapatinib D4 is a potent inhibitor of the receptor tyrosine kinases (RTKs) ErbB1 and ErbB2, which are overexpressed in many breast cancer cases. The deuterated form of Lapatinib has been used in pharmacokinetic studies to help researchers understand the metabolism and distribution of the drug within the body. This information can be useful in optimizing dosing regimens and reducing toxicity.
Lapatinib D4 has a molecular formula of C29H28ClFN4O4S2D4 and a molecular weight of 613.19 g/mol. The deuterated form has four extra hydrogen atoms replaced with deuterium atoms, which can affect the drug's physical and chemical properties. The drug is a yellow to brownish-yellow powder that is soluble in dimethyl sulfoxide (DMSO) and ethanol.
The recommended dosage of Lapatinib D4 varies depending on the patient's weight and the severity of their condition. The drug is usually administered orally in tablet form, and it is important to follow the prescribed dosing schedule to achieve optimal therapeutic effects. Common side effects of Lapatinib D4 may include fatigue, diarrhea, nausea, vomiting, and skin rash. Patients should be monitored closely for signs of toxicity and drug interactions. Overall, Lapatinib D4 is an important tool in the fight against breast cancer, and its unique chemical properties make it a valuable asset in pharmacological research.
Get an Instant Quote
Related Compounds
Lapatinib D4 Ditosylate | Lapatinib D7 | Lapatinib 13C D7 |